Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
出版年份 2013 全文链接
标题
Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
作者
关键词
-
出版物
BRITISH JOURNAL OF CANCER
Volume 109, Issue 6, Pages 1562-1569
出版商
Springer Nature
发表日期
2013-08-14
DOI
10.1038/bjc.2013.456
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
- (2015) Ryan B. Corcoran et al. Oncotarget
- Growth-Inhibitory and Antiangiogenic Activity of the MEK Inhibitor PD0325901 in Malignant Melanoma with or without BRAF Mutations
- (2015) Ludovica Ciuffreda et al. NEOPLASIA
- Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
- (2015) Anwar R. Padhani et al. NEOPLASIA
- Comparisons of the Efficacy of a Jak1/2 Inhibitor (AZD1480) with a VEGF Signaling Inhibitor (Cediranib) and Sham Treatments in Mouse Tumors Using DCE-MRI, DW-MRI, and Histology
- (2015) Mary E. Loveless et al. NEOPLASIA
- Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion-weighted MRI, choline spectroscopy and18F-FLT PET imaging
- (2013) Oussama Karroum et al. Contrast Media & Molecular Imaging
- Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?
- (2012) N Tunariu et al. BRITISH JOURNAL OF CANCER
- The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function
- (2012) L C J Baker et al. BRITISH JOURNAL OF CANCER
- Apparent diffusion coefficient from magnetic resonance imaging as a biomarker in oncology drug development
- (2012) Ralph Sinkus et al. EUROPEAN JOURNAL OF CANCER
- Qualification of imaging biomarkers for oncology drug development
- (2012) John C. Waterton et al. EUROPEAN JOURNAL OF CANCER
- Combinatorial drug therapy for cancer in the post-genomic era
- (2012) Bissan Al-Lazikani et al. NATURE BIOTECHNOLOGY
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of Clinically Translatable MR Imaging Biomarkers of Therapeutic Response in the TH-MYCNTransgenic Mouse Model of Neuroblastoma
- (2012) Yann Jamin et al. RADIOLOGY
- Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR
- (2011) Paul Workman et al. CANCER CELL
- Histone Deacetylase Inhibition Increases Levels of Choline Kinase and Phosphocholine Facilitating Noninvasive Imaging in Human Cancers
- (2011) M. Beloueche-Babari et al. CANCER RESEARCH
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
- (2010) H. Yang et al. CANCER RESEARCH
- A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
- (2010) Jaafar Bennouna et al. INVESTIGATIONAL NEW DRUGS
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- (2010) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gastrointestinal Stromal Tumors Treated with Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients
- (2010) Lei Tang et al. RADIOLOGY
- Diffusion-Weighted MRI of Advanced Hepatocellular Carcinoma During Sorafenib Treatment: Initial Results
- (2009) Christina Schraml et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study
- (2009) R E Board et al. BRITISH JOURNAL OF CANCER
- Quantified Tumor T1 Is a Generic Early-Response Imaging Biomarker for Chemotherapy Reflecting Cell Viability
- (2009) P. M.J. McSheehy et al. CLINICAL CANCER RESEARCH
- From Darkness to Light With Biomarkers in Early Clinical Trials of Cancer Drugs
- (2009) CP Carden et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial
- (2009) Dow-Mu Koh et al. EUROPEAN RADIOLOGY
- MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model
- (2009) S.O. Aliu et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Robust estimation of the apparent diffusion coefficient (ADC) in heterogeneous solid tumors
- (2009) Simon Walker-Samuel et al. MAGNETIC RESONANCE IN MEDICINE
- Early Therapy Evaluation of Combined Anti-Death Receptor 5 Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts by Diffusion-Weighted Magnetic Resonance Imaging
- (2008) H. Kim et al. CANCER RESEARCH
- Biomarkers In Early Clinical Trials: the Committed and the Skeptics
- (2008) U. Banerji et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers
- (2008) Alex A. Adjei et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started